A Phase 1/2 interventional study of IMO-8400 in Waldenstrom's Macroglobulinemia, sponsored by Idera Pharmaceuticals, Inc.. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.
Sponsored by Idera Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 419 studies in Waldenstrom Macroglobulinemia with a site in United States — 34 open to participants now, 57 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · United States.
Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, this one is the 208th largest by enrollment of the 365 interventional ones that give a count, is one of 16 that started in 2014, is one of 48 in phase 1/2, and was the 322nd registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 62 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →34 of the 419 studies in Waldenstrom Macroglobulinemia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Australia, France and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Ascentage Pharma Group Inc. · Sites in United States, China
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Waldenstrom Macroglobulinemia studies recruiting now, 44 (92%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
419 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 188 · Phase 2 210 · Phase 3 20 · Phase 4 2
First in 1988; this study’s year is marked. 16 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 37 across the 365 interventional studies, 106 across the 24 observational. Of the 339 that completed or were terminated, 144 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 419 have an industry lead sponsor. The 10 most frequent:
Idera Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Idera Pharmaceuticals, Inc. has 2 studies filed under Waldenstrom Macroglobulinemia — fewer than ten, so there is no comparison to draw.
17 of the studies in Waldenstrom Macroglobulinemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT05640102BeiGeneObservational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | 2026-12 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT05065554Shayna Sarosiek, MDACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | 2026-12-01 |
| NCT06561347Massachusetts General HospitalZanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is an oligonucleotide specifically designed to inhibit TLRs 7,8, and 9. The scientific hypothesis for use of IMO-8400 to treat patients with Waldenström's macroglobulinemia depends on the inhibition of mutant MYD88 signaling in the TLR pathway, thereby interrupting the proliferation of cell populations responsible for the propagation of the disease.
Eligible subjects will be enrolled and assigned to escalating dose cohorts. Treatment will be administered by subcutaneous injection.
Inclusion Criteria:
Patients must have a diagnosis of Waldenstrom's Macroglobulinemia.
In addition to the above, key inclusion and exclusion criteria are listed below.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMO-8400 at escalating dose levels by subcutaneous injection
Drug: IMO-8400
IMO-8400 at escalating dose levels by subcutaneous injection
Safety and Tolerability of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia
Safety and tolerability of IMO-8400 in patients with Waldenstrom's Macroglobulinemia: Assessment of adverse events
Time frame: Up to 24 weeks
Best Overall Response
Best Overall Response using criteria from the VIth International Workshop in Waldenstrom's Macroglobulinemia
Time frame: Up to 24 weeks
Identify the Number of Patients Experiencing DLTs at Each Dose Level
To identify an appropriate dose of IMO-8400 for further clinical evaluation via evaluation of DLT at each dose level
Time frame: 28 days
Pharmacokinetics of Escalating Dose Levels of IMO 8400 Administered by SC Injection - Cmax.
Pharmacokinetics of escalating dose levels of IMO 8400 administered by SC injection - Cmax.
Time frame: Cycle 1 Week 1 Day 1: Samples were obtained pre-dose (within 1 hr prior to injection) and post-dose at 1 hr (+/-5 min), 2 hrs (+/-10 min) and 4 hrs (+/-15 min)
Pharmacokinetics of Escalating Dose Levels of IMO 8400 Administered by SC Injection - AUC0-t (hr*ng/mL)
Pharmacokinetics of escalating dose levels of IMO 8400 administered by SC injection - AUC0-t (hr\*ng/mL) .
Time frame: Cycle 1 Week 1 Day 1: Samples were obtained pre-dose (within 1 hr prior to injection) and post-dose at 1 hr (+/-5 min), 2 hrs (+/-10 min) and 4 hrs (+/-15 min)
Patients were enrolled from 02 April 2014 through 31 March 2017 at 14 study sites in the United States.
| Milestone | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Started | 6 | 5 | 14 | 6 |
| Completed | 5 | 2 | 5 | 0 |
| Not completed | 1 | 3 | 9 | 6 |
| Withdrew: Adverse event | 0 | 0 | 4 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 2 |
| Withdrew: Miscellaneous | 1 | 1 | 2 | 1 |
Safety and tolerability of IMO-8400 in patients with Waldenstrom's Macroglobulinemia: Assessment of adverse events
| Participants | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| At Least 1 TEAE | 6 | 5 | 14 | 6 |
| At Least 1 Related TEAE | 5 | 2 | 12 | 6 |
| At Least 1 Grade >=3 TEAE | 1 | 2 | 7 | 3 |
| At Least 1 SAE | 0 | 0 | 1 | 2 |
| At Least 1 DLT | 0 | 0 | 1 | 0 |
| At Least 1 TEAE Leading to Death | 0 | 0 | 0 | 0 |
| At Least 1 TEAE Leading to Premature Treatment DC | 0 | 0 | 4 | 2 |
Best Overall Response using criteria from the VIth International Workshop in Waldenstrom's Macroglobulinemia
| Participants | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Very Good Partial Response | 0 | 0 | 0 | 0 |
| Partial Response | 1 | 0 | 2 | 0 |
| Minor Response | 2 | 0 | 4 | 1 |
| Standard Deviation | 2 | 3 | 4 | 3 |
| Progressive Disease | 0 | 1 | 1 | 1 |
| Not Evaluable | 0 | 0 | 1 | 0 |
To identify an appropriate dose of IMO-8400 for further clinical evaluation via evaluation of DLT at each dose level
| Participants | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Identify the Number of Patients Experiencing DLTs at Each Dose Level | 0 | 0 | 1 | 0 |
Pharmacokinetics of escalating dose levels of IMO 8400 administered by SC injection - Cmax.
| Cmax (ng/mL) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Pharmacokinetics of Escalating Dose Levels of IMO 8400 Administered by SC Injection - Cmax. | 807.6 ± 70.3 | 2137.9 ± 68.7 | 2421.2 ± 50.8 | 4433.1 ± 29.9 |
Pharmacokinetics of escalating dose levels of IMO 8400 administered by SC injection - AUC0-t (hr\*ng/mL) .
| AUC0-t (hr*ng/mL) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Pharmacokinetics of Escalating Dose Levels of IMO 8400 Administered by SC Injection - AUC0-t (hr*ng/mL) | 2565.8 ± 64.6 | 6493.0 ± 61.7 | 7229.3 ± 54.5 | 13691.7 ± 32.3 |
Collected over From obtaining informed consent through EOS visit. (up to 24 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMO-8400 0.6 mg/kg 1x/wk | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| IMO-8400 1.2 mg/kg 1x/wk | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| IMO-8400 1.2 mg/kg 2x/wk | 0/14 (0%) | 1/14 (7.1%) | 13/14 (92.9%) |
| IMO-8400 2.4 mg/kg 1x/wk | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 0/6 | 0/5 | 0/14 | 1/6 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/6 | 0/5 | 0/14 | 1/6 |
| SepsisInfections and infestations | 0/6 | 0/5 | 0/14 | 1/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/5 | 0/14 | 1/6 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/6 | 0/5 | 1/14 | 0/6 |
| Event | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 1/6 | 1/5 | 5/14 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/5 | 3/14 | 3/6 |
| NauseaGastrointestinal disorders | 1/6 | 1/5 | 3/14 | 3/6 |
| FatigueGeneral disorders | 1/6 | 1/5 | 5/14 | 3/6 |
| Injection site erythemaGeneral disorders | 3/6 | 0/5 | 0/14 | 0/6 |
| PyrexiaGeneral disorders | 0/6 | 1/5 | 1/14 | 3/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 1/5 | 1/14 | 3/6 |
| Back painMusculoskeletal and connective tissue disorders | 1/6 | 0/5 | 0/14 | 3/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/6 | 0/5 | 1/14 | 3/6 |
| HeadacheNervous system disorders | 0/6 | 2/5 | 3/14 | 2/6 |
Safety Population
| Age, Continuous(years) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Mean | 74.8 ± 12.92 | 70.4 ± 9.71 | 66.5 ± 11.17 | 62.7 ± 11.36 | 68.0 ± 11.53 |
| Sex: Female, Male(Participants) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 1 | 9 |
| Male | 4 | 2 | 11 | 5 | 22 |
| Ethnicity (NIH/OMB)(Participants) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 5 | 14 | 6 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 6 | 5 | 12 | 5 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| United States | 6 | 5 | 14 | 6 | 31 |
| Time Since WM Diagnosis (yrs)(years) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Mean | 7.03 ± 4.62 | 10.16 ± 6.90 | 7.66 ± 3.55 | 5.78 ± 5.22 | 7.58 ± 4.66 |
| Baseline IPSSWM Score(Participants) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Low | 2 | 1 | 5 | 2 | 10 |
| Intermediate | 3 | 3 | 8 | 4 | 18 |
| High | 1 | 1 | 1 | 0 | 3 |
| Baseline Total IgM(mg/dL) | IMO-8400 0.6 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 1x/wk | IMO-8400 1.2 mg/kg 2x/wk | IMO-8400 2.4 mg/kg 1x/wk | Total |
|---|---|---|---|---|---|
| Mean | 1090 ± NA | 2410 ± 973 | 2857 ± 1567 | 2910 ± 1727 | 2715 ± 1473 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2014, a primary completion of Apr 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bazlitoran
Waldenstrom Macroglobulinemia →
Idera Pharmaceuticals, Inc.